Top diabetes tech stories from the first half of 2026. Multi-analyte sensors, insulin patch pumps and regulatory actions have led diabetes tech news in 2026. Here are some highlights of MedTech Dive's coverage. Published July 7, 2026 It's been a busy year for the diabetes technology space, with companies unveiling new technologies, developing products to match their rivals and grappling with regulatory actions that have highlighted quality concerns. At the beginning of the year, the Food and Drug Administration issued a string of warning letters to Abbott, Beta Bionics and Unomedical over quality issues with continuous glucose monitors and insulin pumps. Dexcom disclosed some CGMs it had discarded were stolen and being resold. Companies also announced plans for new diabetes devices and aspirations for expanded insurance coverage. Abbott received a CE mark for a dual glucose-ketone sensor, intended to help people with diabetes avoid a serious complication called diabetic ketoacidosis. Multiple insulin pump makers, including Insulet and MiniMed, discussed plans to design fully closed loop automated insulin delivery systems, which would allow people to manage their diabetes without meal announcements or bolus insulin doses. Meanwhile, Tandem Diabetes Care and Beta Bionics announced timelines for tubeless insulin pumps, which would position them to compete with market leader Insulet. Here are the top stories from the first half of the year. * 4 diabetes tech execs on the future of multi-analyte glucose sensors By Elise Reuter - June 22, 2026 Executives with Abbott, PercuSense and Biolinq spoke with MedTech Dive about what's next with multi-analyte sensor technology. Read the full article | * Diabetes tech companies are racing toward 'fully closed loop' devices. But automation comes with trade-offs. By Elise Reuter - June 4, 2026 Insulet, MiniMed and Tandem Diabetes Care are all working on systems to take meal announcements out of diabetes management. Read the full article | * Abbott receives CE mark for dual glucose-ketone sensor By Elise Reuter - May 27, 2026 Abbott's first dual-analyte sensor comes as competitors are working to develop their own versions of the technology. Read the full article | * Insulet recalls 7M patch pumps due to leak risk By Elise Reuter - May 27, 2026 The recall is Insulet's second this year related to tears in the device tubing. So far, 24 serious adverse events have been reported. Read the full article | * Beta Bionics to launch its first insulin patch pump to compete with Insulet By Elise Reuter - May 26, 2026 The device called Mint, which would work with the company's adaptive insulin dosing algorithm, is expected to debut in the first half of 2027. Read the full article | * Dexcom warns of scrapped glucose sensors being resold By Elise Reuter - May 26, 2026 Dexcom has identified two lots of G7 sensors that have been stolen, sold and used by customers. Read the full article | * Tandem to file tubeless insulin pump with FDA this quarter By Elise Reuter - May 8, 2026 The new version of Tandem's Mobi pump would be the diabetes technology company's first tubeless device. Read the full article | * MiniMed gets FDA nod for smaller insulin pump By Elise Reuter - March 18, 2026 MiniMed Flex is a smartphone-controlled insulin pump about half the size of MiniMed's previous device. It's the company's first launch since separating from Medtronic in early March. Read the full article | * Medtronic's MiniMed goes public for $560M By Elise Reuter - March 6, 2026 The diabetes tech business is now operating as a standalone, public company. Shares began trading on Friday. Read the full article | * FDA warns insulin infusion set maker Unomedical over leaks, mishandled complaints By Elise Reuter - March 2, 2026 Unomedical, which supplies diabetes tech firms including Medtronic, Tandem Diabetes Care and Beta Bionics, received more than 5,000 complaints about leaking infusion sets between 2023 and 2025. Read the full article | * FDA warns Beta Bionics on unreported complaints, insulin pump changes By Elise Reuter - Feb. 26, 2026 The Food and Drug Administration warning letter detailed unreported low blood sugar and a software change to correct for delayed glucose readings. Read the full article | * Abbott receives FDA warning letter over Freestyle Libre CGMs By Elise Reuter - Feb. 3, 2026 Abbott needs to conduct more performance testing to ensure its FreeStyle Libre devices are accurate, FDA inspectors found. Read the full article Filed Under: FDA

Board asks shareholders to approve 3.26m-share increase; TNDM files proxy (TNDM). Filing Impact Filing Sentiment Rhea-AI Filing Summary. Tandem Diabetes Care is holding its 2026 Annual Meeting virtually on May 20, 2026 to vote on seven proposals, including election of nine directors, say-on-pay, an increase of 3,260,000 shares to the 2023 Long-Term Incentive Plan, certificate of incorporation amendments, and ratification of Ernst & Young LLP as auditor. The Record Date shows 68,504,233 shares outstanding as of March 23, 2026. The company reports 2025 business highlights including $1.015 billion in worldwide sales, over 126,000 pump shipments, and several product and regulatory milestones. Insights. Proxy seeks shareholder approval for governance and charter amendments alongside routine meeting items. The proxy presents six board-recommended proposals plus general meeting mechanics for the May 20, 2026 virtual meeting and discloses 68,504,233 shares outstanding as of March 23, 2026. Two charter amendments are proposed: a Section 141(k) removal amendment and an officer exculpation amendment tied to recent DGCL changes. Key dependencies include supermajority vote thresholds: the Section 141(k) and Officer Exculpation Amendments each require 66 2/3% approval. Subsequent filings will report vote results in a Form 8-K within four business days after the meeting. Board requests a 3,260,000-share increase to the 2023 equity plan and summarizes 2025 pay outcomes. The board proposes adding 3,260,000 shares to the 2023 Long-Term Incentive Plan and discloses current availability and activity metrics: 729,748 shares available as of March 16, 2026, a 2025 burn rate of 3.1%, and historical grants shown through March 16, 2026. The plan retains features such as minimum 12-month vesting, anti-repricing, clawback provisions, and director grant caps. Outcomes will hinge on shareholder approval; if not approved, the company states it may exhaust current reserves and be unable to grant customary awards thereafter. 03/27/2026 - 04:07 PM | / | / | / | / | / | / | / | / | / | Value of initial fixed $100 investment based on: | / | / | / | / | | Year | Summary Compensation Table Total for PEO(1) | / | CAP to PEO(1)(3) | / | Average Summary Compensation Table Total for Non-PEO NEOs(2) | / | Average CAP to Non-PEO NEOs(2)(3) | / | Total Shareholder Return(4) | / | Peer Group Total Shareholder Return TSR(4) | / | Net Income (loss) ($ in millions)(5) | / | Sales ($ in millions)(6) | | 2025 | $ | 6,858,503 | / | / | $ | 2,919,024 | / | / | $ | 1,970,448 | / | / | $ | 1,579,586 | / | / | $ | 22.97 | / | / | $ | 99.39 | / | / | $ | (204.7) | / | / | $ | 1,014.7 | / | | 2024 | $ | 8,526,238 | / | / | $ | 6,793,928 | / | / | $ | 1,945,074 | / | / | $ | 1,752,852 | / | / | $ | 60.43 | / | / | $ | 105.42 | / | / | $ | (96.0) | / | / | $ | 940.2 | / | | 2023 | $ | 4,651,603 | / | / | $ | 1,510,100 | / | / | $ | 1,497,536 | / | / | $ | 1,086,227 | / | / | $ | 49.62 | / | / | $ | 106.34 | / | / | $ | (222.6) | / | / | $ | 747.7 | / | | 2022 | $ | 6,378,515 | / | / | $ | (8,343,937) | / | / | $ | 1,746,125 | / | / | $ | (3,175,063) | / | / | $ | 75.41 | / | / | $ | 99.81 | / | / | $ | (94.6) | / | / | $ | 801.2 | / | | 2021 | $ | 5,739,882 | / | / | $ | 16,412,581 | / | / | $ | 1,616,639 | / | / | $ | 5,058,736 | / | / | $ | 252.51 | / | / | $ | 125.43 | / | / | $ | 15.6 | / | / | $ | 702.8 | / | 2) The non-PEO NEOs, for each year reported were as follows: - 2025: Elizabeth A. Gasser, Shannon Hansen, Mark D. Novara and Leigh A. Vosseller - 2024: Elizabeth A. Gasser, Jean-Claude Kyrillos, Susan M. Morrison, Mark D. Novara and Leigh A. Vosseller - 2023: David B. Berger, Elizabeth A. Gasser, Brian B. Hansen, Susan M. Morrison, Mark D. Novara and Leigh A. Vosseller - 2022: David B. Berger, Elizabeth A. Gasser, Brian B. Hansen, Susan M. Morrison and Leigh A. Vosseller - 2021: David B. Berger, Elizabeth A. Gasser, Brian B. Hansen, Susan M. Morrison and Leigh A. Vosseller | Year | Executive(s) | / | Summary Compensation Table Total | / | Deduct: Stock Awards Granted in Year | / | Add: Year-End Fair Value of Unvested Equity Awards Granted in Year* | / | Add: Change in Year-End Fair Value of Unvested Equity Awards Granted in Prior Years | / | Add: Change in Year-End Fair Value of Equity Awards Granted in Prior Years Which Vested in Year | / | CAP | / | / | / | / | | 2025 | PEO | / | $ | 6,858,503 | / | / | $ | (5,367,796) | / | / | $ | 5,240,252 | / | / | $ | (2,611,510) | / | / | $ | (1,200,425) | / | / | $ | 2,919,024 | / | / | / | / | / | | Non-PEO NEOs | / | $ | 1,970,448 | / | / | $ | (1,226,792) | / | / | $ | 1,197,646 | / | / | $ | (166,600) | / | / | $ | (195,116) | / | / | $ | 1,579,586 | / | / | / | / | / | | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | * The valuation assumptions used to calculate fair values did not materially differ from those disclosed at the time of grant. 6) As required by Item 402(v) of Regulation S-K, we have determined that Sales is the Company-Selected Measure. * Annual sales for 2024, 2023 and 2022 include the effect of net sales recognized (deferred) of $30.2 million, ($25.1) million and ($3.5) million, respectively. This related to the accounting treatment associated with our Tandem Choice Program offering, which began in September 2022 and ended December 31, 2024, to provide a pathway to eligible t:slim X2 customers to ownership of our newest hardware platform, Tandem Mobi, for a fee when available. There was no comparative adjustment to pump sales in 2025. | Most Important Performance Measures Used to Link CAP to Company Performance: | | Sales | | Gross Margin | | Adjusted EBITDA Margin* | | New Product Launch Timing | | Customer Satisfaction | | / | We have not granted stock options, stock appreciation rights, or similar instruments with option-like features since 2022 and have no policies or practices to disclose pursuant to Item 402(x)(1) of Regulation S-K. Faq. What is Tandem Diabetes Care (TNDM) voting on at the 2026 annual meeting? The company asks shareholders to elect nine directors and vote on six additional items. These include say-on-pay, a 3,260,000 -share increase to the 2023 equity plan, two charter amendments, and ratification of Ernst & Young LLP as auditor. When and how will TNDM shareholders vote at the 2026 Annual Meeting? The virtual meeting is scheduled for May 20, 2026 at 3:00 p.m. Pacific time. Shareholders may vote by internet, telephone, mail, or during the webcast using the 16-digit control number or QR code provided in proxy materials. How many Tandem (TNDM) shares were outstanding for voting purposes? There were 68,504,233 shares of Common Stock outstanding as of the Record Date, March 23, 2026, and each share is entitled to one vote on meeting matters. What change to the 2023 Long-Term Incentive Plan is being proposed? The board proposes to increase the number of shares authorized under the 2023 Plan by 3,260,000 shares and describes governance features like a minimum 12-month vesting rule and a director grant cap of $750,000 per fiscal year. What voting thresholds apply to the charter amendments in the proxy for TNDM? Approval of the Section 141(k) Amendment and the Officer Exculpation Amendment each requires the affirmative vote of holders of at least 66 2/3% of outstanding common shares on the Record Date. What financial highlights from 2025 does Tandem disclose in the proxy? The proxy cites more than $1.015 billion in worldwide sales for 2025, record Q4 sales above $290 million, and over 126,000 annual pump shipments, along with product rollouts and an FDA clearance of Control-IQ+ for type 2 diabetes.

Tandem Diabetes Care has expanded its Tandem Mobi automated insulin delivery system to compatible Android smartphones in the US, following FDA clearance in November 2025 and a limited release in December. The Android rollout broadens accessibility for Mobi users and strengthens the company's position in smartphone-based diabetes management. The expansion supports Tandem's investment thesis by widening accessibility and reinforcing ecosystem retention, though near-term pressures remain from flat renewal expectations and ongoing losses. Combined with October 2025's integration of t:slim X2 with Abbott's FreeStyle Libre 3 Plus CGM, the move demonstrates a broader connectivity strategy. Tandem's narrative projects $1.2 billion revenue and $14.4 million earnings by 2028, requiring 7.5% yearly revenue growth. The company's 2026 sales guidance stands at approximately $1.065 billion to $1.085 billion.